Therapeutic NOTCH3 cysteine correction in CADASIL using exon skipping: in vitro proof of concept.
暂无分享,去创建一个
G. van Ommen | Annemieke Aartsma-Rus | H. Venselaar | D. Peters | C. Haffner | J. Rutten | H. Dauwerse | A. Goldfarb | S. L. Lesnik Oberstein
[1] W. V. van Roon-Mom,et al. Antisense oligonucleotides in therapy for neurodegenerative disorders. , 2015, Advanced drug delivery reviews.
[2] K. Davies,et al. Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers , 2015, Nature Medicine.
[3] U. Lendahl,et al. Notch3 Is Necessary for Blood Vessel Integrity in the Central Nervous System , 2015, Arteriosclerosis, thrombosis, and vascular biology.
[4] V. Ricotti,et al. Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study , 2014, The Lancet Neurology.
[5] S. Iannaccone,et al. Spinal Muscular Atrophy: Therapeutic Strategies , 2014, Current Treatment Options in Neurology.
[6] G. Terwindt,et al. Interpretation of NOTCH3 mutations in the diagnosis of CADASIL , 2014, Expert review of molecular diagnostics.
[7] J. Dauwerse,et al. Hypomorphic NOTCH3 Alleles Do Not Cause CADASIL in Humans , 2013, Human mutation.
[8] A. Joutel,et al. Abnormal recruitment of extracellular matrix proteins by excess Notch3 ECD: a new pathomechanism in CADASIL. , 2013, Brain : a journal of neurology.
[9] K. McKeage,et al. Mipomersen Sodium: First Global Approval , 2013, Drugs.
[10] E. Kremmer,et al. Co-aggregate formation of CADASIL-mutant NOTCH3: a single-particle analysis. , 2011, Human molecular genetics.
[11] M. Dichgans,et al. CADASIL , 2009, The Lancet Neurology.
[12] M. Baumann,et al. Evolutionary scenarios of Notch proteins. , 2009, Molecular biology and evolution.
[13] G. van Ommen,et al. Theoretic applicability of antisense‐mediated exon skipping for Duchenne muscular dystrophy mutations , 2009, Human mutation.
[14] A. Moorman,et al. Amplification efficiency: linking baseline and bias in the analysis of quantitative PCR data , 2009, Nucleic acids research.
[15] P. Handford,et al. A conserved face of the Jagged/Serrate DSL domain is involved in Notch trans-activation and cis-inhibition , 2008, Nature Structural &Molecular Biology.
[16] R. Kole,et al. Efficient and persistent splice switching by systemically delivered LNA oligonucleotides in mice. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.
[17] S. Saiki,et al. Varicose veins associated with CADASIL result from a novel mutation in the Notch3 gene , 2006, Neurology.
[18] T. Tabira,et al. CADASIL-causing mutations do not alter Notch3 receptor processing and activation , 2006, Neuroreport.
[19] G. van Ommen,et al. Functional analysis of 114 exon-internal AONs for targeted DMD exon skipping: indication for steric hindrance of SR protein binding sites. , 2005, Oligonucleotides.
[20] Tan Xiao-mei,et al. CADASIL , 2005 .
[21] B. Klonjkowski,et al. Notch3 is required for arterial identity and maturation of vascular smooth muscle cells. , 2004, Genes & development.
[22] M. Dichgans,et al. CADASIL-associated Notch3 mutations have differential effects both on ligand binding and ligand-induced Notch3 receptor signaling through RBP-Jk. , 2004, Experimental cell research.
[23] Lawrence J Marnett,et al. A Novel Mechanism of Cyclooxygenase-2 Inhibition Involving Interactions with Ser-530 and Tyr-385* , 2003, Journal of Biological Chemistry.
[24] U. Lendahl,et al. A CADASIL-mutated Notch 3 receptor exhibits impaired intracellular trafficking and maturation but normal ligand-induced signaling , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[25] M. Reiser,et al. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy: decrease in regional cerebral blood volume in hyperintense subcortical lesions inversely correlates with disability and cognitive performance. , 2001, AJNR. American journal of neuroradiology.
[26] M. Dichgans,et al. Reduced Cerebrovascular CO2 Reactivity in CADASIL: A Transcranial Doppler Sonography Study , 2001, Stroke.
[27] G. Weinmaster,et al. Fringe differentially modulates Jagged1 and Delta1 signalling through Notch1 and Notch2 , 2000, Nature Cell Biology.
[28] F. Chapon,et al. The ectodomain of the Notch3 receptor accumulates within the cerebrovasculature of CADASIL patients. , 2000, The Journal of clinical investigation.
[29] J. Weissenbach,et al. Strong clustering and stereotyped nature of Notch3 mutations in CADASIL patients , 1997, The Lancet.
[30] J. Weissenbach,et al. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia , 1996, Nature.
[31] David W. Banner,et al. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor , 1996, Nature.
[32] U. Lendahl,et al. The novel Notch homologue mouse Notch 3 lacks specific epidermal growth factor-repeats and is expressed in proliferating neuroepithelium , 1994, Mechanisms of Development.
[33] G Vriend,et al. WHAT IF: a molecular modeling and drug design program. , 1990, Journal of molecular graphics.
[34] Annemieke Aartsma-Rus,et al. Overview on applications of antisense-mediated exon skipping. , 2012, Methods in molecular biology.
[35] D. Leys,et al. Systemic vascular smooth muscle cell impairment in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy , 2004, Acta Neuropathologica.
[36] K. Kosik,et al. Distribution pattern of Notch3 mutations suggests a gain-of-function mechanism for CADASIL. , 2004, Genomics.